A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main
objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose)
in cancer patients pre treated or unresponsive to standard therapies.